Asset comparator
Compare stocks, ETFs, indices, commodities, cryptocurrencies and bonds over the same period. Indicators that are not meaningful for a given asset type are flagged.
- Pharmaron Beijing Co., Ltd.
- Hansoh Pharmaceutical Group
Comparative performance (base 100)
Each asset is worth 100 at October 20, 2025; a value of 120 means +20% since that date (latest common date: October 16, 2026).
Indicators
"Not applicable" indicates a metric that has no meaning for this type of asset: it should not be compared.
| Indicator | Pharmaron Beijing Co., Ltd.Stock | Hansoh Pharmaceutical GroupStock |
|---|---|---|
| Performance and risk | ||
| Performance over the periodChange in price between the first and last common dates. | +9.4% | −12.9% |
| Annualized performanceAverage annual return that would produce the same total performance. | +9.5% | −13.0% |
| Annualized volatilityTypical range of price movements: the higher it is, the more the price fluctuates. | 50.5% | 41.1% |
| Maximum DrawdownLargest decline from peak to subsequent trough over the period. | −42.6% | −34.1% |
| Sharpe RatioReturn achieved above the risk-free rate (5.10%), per unit of volatility. The higher it is, the better risk was rewarded over the period. | 0.38 | -0.26 |
| 1-day 95% Value at RiskOne-day loss that was exceeded in only 5% of cases (historical VaR). | −4.7% | −3.8% |
| Fundamentals | ||
| Market capitalizationTotal market value of all shares (or circulating tokens for a crypto). | 48.5B HKD | 192.43B HKD |
| P/E (trailing 12 months)Share price divided by earnings per share: number of years of earnings paid. | 25.6 | 25.8 |
| Price-to-SalesMarket capitalization divided by annual revenue. | 3.2 | 12.1 |
| Net marginShare of revenue retained as profit. | 11.2% | 42.0% |
| Return on equityReturn on equity (ROE). | 10.1% | 19.4% |
| Revenue growthOver one year, latest published quarter compared with the same quarter of the previous year. | +20.2% | +11.7% |
| Dividend yieldAnnual dividend relative to the share price. | 0.87% | 1.53% |
| Debt / equityFinancial debt relative to shareholders' equity. | 41% | 11% |
Correlations over the period
From −1 to 1: close to 1, the two assets rise and fall together; close to 0, they move independently.
- Pharmaron Beijing Co., Ltd. / Hansoh Pharmaceutical Group0.48
Information provided for educational purposes only. It does not constitute investment advice or a personalized recommendation. Past performance is no guarantee of future results.